Overview

Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The investigators will randomize smokers to receive 1) Varenicline + smoking cessation/reduction counseling or 2) Placebo pill + smoking cessation/reduction counseling. Neither the participants nor the research therapists/evaluators will know to which condition (active or placebo pill) the participants have been assigned i.e., a double-blind study). The medication and weekly counseling will occur for 28 days. Participants will complete assessment measures just before the start of treatment (baseline), at the end-of-treatment, at 1-month, 3-month, and at 6-months to determine if there are differences in tobacco use between treatment groups.
Phase:
N/A
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborator:
Pfizer
Treatments:
Varenicline